Top Clinical Trials companies in Italy by Debt to Equity Ratio

This ranking features the top 2 Clinical Trials companies in Italy ranked by Debt to Equity Ratio, averaging a Debt to Equity Ratio of -0.73, for February 06, 2025.

Italy

Clinical Trials
Debt to Equity Ratio
#
Name
Debt to Equity Ratio
 Reported Date
Stock Price
Change
 Price (30 days) Country
1
PHIL.MI

Philogen S.p.A.

1

PHIL.MI
0.16
Dec. 31, 2023 USD 19.14 -0.29%

Italy
2
NP5.DE

Newron Pharmaceuticals S.p.A.

2

NP5.DE
-1.62
Dec. 31, 2023 USD 10.86 4.76%

Italy
Frequently Asked Questions
  • Which Clinical Trials company in Italy has the highest Debt to Equity Ratio ?

    The Clinical Trials company in Italy with the highest Debt to Equity Ratio is Philogen S.p.A. (Milan Stock Exchange: PHIL.MI) at 0.16.

  • Which Clinical Trials company in Italy has the lowest Debt to Equity Ratio ?

    The Clinical Trials company in Italy with the lowest Debt to Equity Ratio is Newron Pharmaceuticals S.p.A. (XETRA: NP5.DE) at -1.62.

SV Wall Street